home / stock / asnd / asnd articles

ASND Articles, Ascendis Pharma A/S

Stock Information
Company Name: Ascendis Pharma A/S
Stock Symbol: ASND
Market: NASDAQ
Website: ascendispharma.com
Menu
ASND ASND Quote ASND Short ASND News ASND Articles ASND Message Board
Get ASND Alerts

News, Short Squeeze, Breakout and More Instantly...
Macy's, Ascendis Pharma And 3 Stocks To Watch Heading Into Friday | Benzinga

With U.S. stock futures trading higher on Friday morning, some of the stocks that may grab investor focus today are as follows: Arkhouse Managemen...
Here's How Much $1000 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today | Benzinga

Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 15 years by 15.29% on an annualized basis producing an average annual retur...

Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 15 Years | Benzinga

Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 15 years by 15.22% on an annualized basis producing an average annual retur...

If You Invested $100 In This Stock 15 Years Ago, You Would Have $4,100 Today | Benzinga

Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 15 years by 16.47% on an annualized basis producing an average annual retur...
Ascendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024 | Benzinga

COPENHAGEN, Denmark, May 30, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that it will host informational booths, ...

$100 Invested In This Stock 10 Years Ago Would Be Worth $6,500 Today | Benzinga

Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 41.19% on an annualized basis producing an average annual retur...

FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months | Benzinga

Tuesday, Ascendis Pharma A/S (NASDAQ:ASND) announced that the FDA extended the review date for TransCon PTH (palopegteriparatide) for adu...
$100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth This Much Today | Benzinga

Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 15 years by 16.63% on an annualized basis producing an average annual retur...

Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024 | Benzinga

COPENHAGEN, Denmark, April 25, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it will report first quarter 2024 fina...

$1000 Invested In Ascendis Pharma 15 Years Ago Would Be Worth This Much Today | Benzinga

Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 15 years by 17.87% on an annualized basis producing an average annual retur...
Next 10